Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

plasmacytoma - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

plasmacytoma

MONDO:0005615

Also known as:solitary plasmacytomaanaplastic plasmacytomaanaplastic skeletal plasmacytoma (type)

Find Clinical TrialsTrials

Overview

Plasmacytoma is a localized mass of neoplastic monoclonal plasma cells that represents approximately 5% of all plasma cell neoplasms. There are two separate entities: primary plasmacytoma of the bone and extramedullary plasmacytoma of the soft tissues. Of the extramedullary plasmacytomas, 80% occur in the head and neck, usually in the upper respiratory tract. The median age at diagnosis is 50 years and the male to female ratio is 3:1. Long-term survival is possible following local radiotherapy, particularly for soft tissue presentations.

Clinical Trials10 registered · 3 recruiting

Diagnosis

Biomarker and diagnostic research for plasmacytoma has been reported in the published literature.

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

10 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 1 PHASE3, 5 PHASE2, 3 PHASE1. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07115667](https://clinicaltrials.gov/study/NCT07115667)

Data assembled from 4 of 12 sources · Last updated Sep 17, 2026, 9:28 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:86855

GARD

Genetic and Rare Diseases Info Center

GARD:13446

Questions for Your Care Team

→Are any of the 10 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	58	41%
Research summaries	35	25%
Disease patterns and progression	14	10%
Testing and diagnosis research	10	7%
Laboratory research	10	7%
Clinical study results	9	6%
Other research	5	4%
New treatment approaches	1	1%

Kisho

plasmacytoma

Overview

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.

plasmacytoma

Overview

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.